Tag: ad

Framkvæmdasýslan - Ríkiseignir hefur tilkynnt Reitum að tilboði félagsins í útboði um uppbyggingu nýs hjúkrunarheimilis á Akureyri hafi verið valið og metið hagstæðast samkvæmt valforsendum útboðslýsingar. 

Integration brings deeper audience intelligence to out-of-home planning, targeting and campaign performance across Quebecor’s Out-of-Home network

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex’s leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

邁阿密, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs 作為主題與槓桿型交易所買賣基金 (ETF) 領導先鋒，今天宣佈 Defiance Daily 2X Space ETF (Cboe BZX: SPCL) 的股份已被 Cboe BZX Exchange, Inc.（「交易所」）暫時停止買賣。

マイアミ発, June 14, 2026 (GLOBE NEWSWIRE) -- テーマ型およびレバレッジ型上場投資信託 (ETF) のリーダーであるディファイアンスETFs (Defiance ETFs) は本日、ディファイアンス・デイリー2XスペースETF (Defiance Daily 2X Space ETF) (Cboe BZX: SPCL) の取引が、シーボーBZX取引所 (Cboe BZX Exchange, Inc.) (以下「同取引所」) により一時停止されたことを発表した。

北京発 , June 14, 2026 (GLOBE NEWSWIRE) -- セントオート・オートモーティブ・コミュニケーション・カンパニー (Sentauto Automotive Communication Company) は、「1997年から新時代へ：フリーランダーがランドローバーのDNAを現代的デザインにどう再解釈したか (From 1997 to a New Era: How FREELANDER Reinterprets Its Land Rover DNA into Modern Design)」というニュース記事を掲載した。 記事全文はこちらからアクセス可能である： https://www.sentauto.com/news/907.html。

アレルギー分野の第一線の専門家がイスタンブールに集結し、科学、予防、政策がいかにしてアレルギー疾患の世界的な影響を軽減できるかを検討する

세계 알레르기 전문가들, 이스탄불에 모여 과학·예방·정책을 통한 질환 부담 감소 방안 논의

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.¹ The results showed that TALVEY^® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).¹ Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.¹